Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Free Cash Flow (2016 - 2025)

Traws Pharma (TRAW) has disclosed Free Cash Flow for 14 consecutive years, with -$4.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 65.05% to -$4.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$19.5 million, a 35.5% increase, with the full-year FY2024 number at -$33.4 million, down 86.34% from a year prior.
  • Free Cash Flow was -$4.0 million for Q3 2025 at Traws Pharma, up from -$6.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$3.9 million in Q4 2022 to a low of -$11.5 million in Q3 2024.
  • A 5-year average of -$5.2 million and a median of -$4.4 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 156.79% in 2024, then soared 65.05% in 2025.
  • Traws Pharma's Free Cash Flow stood at -$4.3 million in 2021, then rose by 8.93% to -$3.9 million in 2022, then fell by 14.06% to -$4.4 million in 2023, then grew by 8.8% to -$4.0 million in 2024, then rose by 0.72% to -$4.0 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Free Cash Flow are -$4.0 million (Q3 2025), -$6.0 million (Q2 2025), and -$5.4 million (Q1 2025).